BCR and pachyonychia congenita: PSMA-11 PET showed promising potential in identifying the sites of BCR because of the high-affinity binding of PSMA to folate hydrolase of PC cells [25], and is gaining worldwide popularity as a clinically relevant staging tool, even in men with low PSA levels (i.e. <1 ng/ml) at recurrence [26].